ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).
We believe that the best-cleft care is provided by an integrated team of specialists that includes surgery, dentistry, psychology, nursing, and anesthesiology.